

<b>Report to:</b>	NHS Hull Clinical Commissioning Board
<b>Date of Meeting:</b>	22 May 2020
<b>Subject:</b>	Corporate Risk Register
<b>Presented by:</b>	Mike Napier, Associate Director of Corporate Affairs
<b>Author:</b>	Mike Napier, Associate Director of Corporate Affairs / Risk Owners

**STATUS OF THE REPORT:**

To approve	<input type="checkbox"/>	To endorse	<input type="checkbox"/>
To ratify	<input type="checkbox"/>	To discuss	<input type="checkbox"/>
To consider	<input checked="" type="checkbox"/>	For information	<input type="checkbox"/>
To note	<input type="checkbox"/>		

**PURPOSE OF REPORT:**  
The purpose of this report is to brief Board Members on the current corporate risk register and describe the changes on the register in the interim period since previously reviewed by the Board.

**RECOMMENDATIONS:**  
It is recommended that the Board Members note the updates provided and comment, where appropriate, on the adequacy of the controls, assurances and mitigations within the corporate risk register.

**REPORT EXEMPT FROM PUBLIC DISCLOSURE**      No       Yes

If yes, grounds for exemption  
(FOIA or DPA section reference)

**CCG STRATEGIC OBJECTIVE**

Specific risks to achievement of the CCG's strategic objectives are set out within the Board Assurance Framework. The corporate risk register is regularly reviewed to establish whether any new risks emerge that relate to a strategic objective, in which case they transfer on to the BAF.

**IMPLICATIONS:**

Finance	All risks are assessed for their capacity to specifically impact on finance, HR, quality and safety. Where a negative impact is identified this is set out within the specific risk narrative.
HR	
Quality	
Safety	

**ENGAGEMENT:**

Each risk on the corporate risk register is owned by a CCG senior officer. They are all subject to regular review by them as well as relevant teams and meetings.

**LEGAL ISSUES:**

Individual risks may highlight threats to achievement of the CCG's statutory duties. In such instances the implications and consequences

**EQUALITY AND DIVERSITY ISSUES:**

	<i>Tick relevant box</i>
An Equality Impact Analysis/Assessment is not required for this report.	√
An Equality Impact Analysis/Assessment has been completed and approved by the lead Director for Equality and Diversity. As a result of performing the analysis/assessment there are no actions arising from the analysis/assessment.	
An Equality Impact Analysis/Assessment has been completed and there are actions arising from the analysis/assessment and these are included in section xx in the enclosed report.	

**THE NHS CONSTITUTION:**

This report supports the NHS pledge to staff and all aspects of the patients' rights.

# CORPORATE RISK REGISTER

## 1. INTRODUCTION

- 1.1. The purpose of this report is to brief Board Members on the current corporate risk register and describe the changes on the register in the interim period since previously reviewed by the Board.

## 2. BACKGROUND

- 2.1. The CCG maintains a comprehensive risk register sets out the full range of risks to achievement of CCG objectives. The corporate risk register comprises those risks on the risk register with a risk rating of high or extreme.
- 2.2. Individual risk owners are responsible for updating, reviewing and managing their risks. The risk register in its entirety is a standing agenda item at team meetings and the Health, Safety and Security Committee for discussion. It is also considered regularly at the main committees of the Board.
- 2.3. The corporate risk register is reviewed in detail at each meeting of the Integrated Audit and Governance Committee as well as bi-annually by the CCG Board.
- 2.4. Following discussions at the CCG's Integrated Audit and Governance Committee, risk owners were advised of an updated approach to the risk register during this period where efforts continue to be focused primarily on supporting the coronavirus response. It was recognised that there were significant operational changes both within the CCG and our partners such that it may not be possible to give full updates to all of the risks set out within the Corporate Risk Register in the short term.

This approach is summarised as follows:

- A lighter touch to the review process will be adopted by the IACG, with primary focus given to existing *or new* risks which related to the pandemic.
- For the remaining existing risks, individual risk owners are still asked to highlight / update any of their risks where they believed there is deterioration in the controls, assurances or risk rating of the risk.

This approach will be kept under review in advance of the subsequent IAGC meeting in July.

Work is also underway to reflect the emerging organisational risks associated with the pandemic major incident response and recovery phases and these will be reviewed at the next IAGC meeting.

## 3. RECOMMENDATIONS

- 3.1 It is recommended that the Board Members note the updates provided and comment, where appropriate, on the adequacy of the controls, assurances and mitigations within the corporate risk register.